The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- down regulace MeSH
- duktální karcinom pankreatu genetika patologie MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy MeSH
- membránové transportní proteiny genetika MeSH
- míra přežití MeSH
- mutace MeSH
- nádory slinivky břišní genetika patologie MeSH
- prognóza MeSH
- prospektivní studie MeSH
- proteiny přenášející organické kationty genetika MeSH
- protoonkogenní proteiny p21(ras) MeSH
- protoonkogenní proteiny genetika MeSH
- Ras proteiny genetika MeSH
- regulace genové exprese u nádorů MeSH
- sekvenční analýza DNA MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- upregulace MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- KRAS protein, human MeSH Prohlížeč
- membránové transportní proteiny MeSH
- proteiny přenášející organické kationty MeSH
- protoonkogenní proteiny p21(ras) MeSH
- protoonkogenní proteiny MeSH
- Ras proteiny MeSH
OBJECTIVES: The aim of this study was to investigate the prognostic significance of fourteen anticancer drug-relevant solute carrier transporters (SLCs) in pancreatic cancer in the context of clinical-pathological characteristics and the KRAS mutation status of tumors. METHODS: Tumors and non-neoplastic pancreatic tissues were obtained from 32 histologically verified patients with pancreatic ductal adenocarcinoma. The transcript profile of SLCs was assessed using quantitative real-time PCR. KRAS mutations in exon 2 were assessed by high-resolution melting analysis and confirmed by sequencing. RESULTS: SLC22A3 and SLC22A18 were upregulated and SLC22A1, SLC22A2, SLC22A11, SLC28A1, SLC28A3 and SLC29A1 were downregulated when compared with non-neoplastic pancreatic tissues. Moreover, significantly lower levels of SLC22A1, SLC22A11 and SLC29A1 were found in tumors with angioinvasion. There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis. The study found that a high expression of SLC28A1 was significantly associated with poor overall survival in unselected patients. In contrast, a high expression of SLC22A3 or SLC29A3 was significantly associated with longer overall survival in patients treated with nucleoside analogs. Protein expression of SLC22A1, SLC22A3 and SLC29A3 in tumor tissues of patients with pancreatic carcinoma was observed by immunoblotting for the first time. Finally, SLC levels were not found to be associated with KRAS mutation status in exon 2. CONCLUSIONS: This study identified a number of associations of transcript levels of SLCs with prognosis of pancreatic cancer patients.
Citace poskytuje Crossref.org
SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma
Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma
KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes
Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy
